Canada Medical Device Registration: 20 FAQs on MDL, MDEL, Classification and MDSAP (2026)

Canada is not a “mini FDA”, nor a “simplified CE”. It runs on a regulatory logic of its own: two licences, four risk classes, one mandatory MDSAP system certificate, and a set of post-market reporting clocks ranging from 10 days down to 72 hours.

This article answers 20 questions on Canadian medical device registration, each verified line by line against Canada’s Food and Drugs Act and the Medical Devices Regulations (SOR/98-282, consolidated version current as of September 30, 2026, most recently amended June 17, 2026). Every answer is followed by the section number so you can verify it yourself.

Wherever an answer reflects practical judgement rather than the letter of the regulation, it is explicitly flagged as such.

Part 1: The Framework and the Pathways – Who Regulates What, and How Many Licences You Need

Q1 Who regulates medical devices in Canada, and under which laws?

Bottom line: The Medical Devices Directorate (MDD) of Health Canada is the regulator. The overarching statute is the Food and Drugs Act, and the operative rules are the Medical Devices Regulations (SOR/98-282).

Three layers must be distinguished:

• Statute: the Food and Drugs Act – it empowers the Minister to issue licences, order recalls, request information, and more;
• Regulation: the Medical Devices Regulations – all technical requirements on classification, licensing, labelling, reporting and recalls;
• Guidance: the various guidance documents published by Health Canada (e.g., GUI-0016, GUI-0054) – administrative documents with no legal force, but Health Canada explicitly states that deviations from guidance require adequate justification and prior communication with the authority.

Basis: Section 1 (interpretation) of the Medical Devices Regulations states that the Regulations are made under sections 3(3), 30(1) and 37(1) of the Food and Drugs Act; the provision text is available in the Department of Justice Canada regulations database at laws-lois.justice.gc.ca.

Tip: To judge whether a claim is reliable, first check whether it cites “section X of the Regulations” or “section X of a guidance document”. The former is a hard constraint; the latter is a negotiable operating position.

Q2 How many device classes are there, and who decides classification?

Bottom line: Four classes, Class I through Class IV, with Class I the lowest risk and Class IV the highest. Classification follows the classification rules in Schedule 1 of the Regulations – non-IVDD devices apply Part I and IVDD devices apply Part II, and the two sets of rules are independent.

Section 6 of the Regulations, verbatim: medical devices are classified into one of classes I to IV under the classification rules in Schedule 1, where Class I represents the lowest risk and Class IV represents the highest risk.

Section 7 is an easily overlooked “stricter rule”: if a device could fall into more than one class, the higher-risk class applies.

Classification is determined by the manufacturer, which is responsible for its determination. If in doubt, a formal classification request may be submitted to the MDD.

Basis: Sections 6 and 7 and Schedule 1 of the Regulations; the classification request channel is described in the instructions for Health Canada’s establishment licence application form FRM-0292.

Practical reminder: a classification error is one of the costliest mistakes in a Canadian submission – establishment licence fees are non-refundable, and the wrong class causes all subsequent application material to be prepared at the wrong depth.

Q3 How many types of licences does Canada have, and what exactly is the difference between an MDL and an MDEL?

Bottom line: Two licences with completely different logic; both are indispensable.

One-line memory aid: the MDL governs “whether this product can be sold”, while the MDEL governs “whether you are qualified to bring goods into Canada”.

Basis: Section 26 of the Regulations (Class II, III and IV devices must not be imported or sold without a licence) and section 44 (no importation or sale without an establishment licence); Health Canada’s Guidance on medical device establishment licensing (GUI-0016).

Q4 Must foreign manufacturers appoint a representative in Canada?

Bottom line: No. Canada has no EU-style “authorised representative” system.

This is the most fundamental difference between Canada and markets such as the EU, Thailand and Indonesia, and the place where many Chinese companies most easily apply the wrong template:

• The licence holder is the manufacturer itself. The MDL is issued to the manufacturer; a foreign manufacturer can hold it directly, with no local entity acting on its behalf.
• Manufacturers of Class II, III and IV devices are exempt from the MDEL. Section 44(2)(c) of the Regulations is explicit: the establishment licence requirement in section 44(1) does not apply to a manufacturer importing or selling a Class II, III or IV device it manufactures.
• But to get goods into Canada, an importer holding an MDEL is still needed. Section 44(1) provides that no person shall import or sell a medical device unless they hold an establishment licence. Section 44(3) further requires importers to ensure that their upstream supplier holds an establishment licence (except when importing directly from a Class II-IV manufacturer).

So the correct pathway picture is not “find a Canadian agent”, but: the foreign manufacturer holds the MDL (product access) + the Canadian importer holds the MDEL (entity qualification) + a quality agreement and authorisation documents between the two parties.

There is also an optional role: the regulatory correspondent. A manufacturer may voluntarily designate one to receive Health Canada’s annual renewal package and correspondence; if none is designated, these are sent directly to the manufacturer. It is not a legally required role, but missing a change notification can lead to licence cancellation, so manufacturers are strongly advised to appoint a professional regulatory contact to keep compliance continuous.

Basis: Sections 44(1)(2)(c)(3)(4) of the Regulations; Health Canada’s Guidance Document – Medical Device Licence Renewal and Fees for the Right to Sell Licensed Medical Devices.

Q5 Does Class I mean “no registration required”?

Bottom line: No MDL is required, but that is by no means “no compliance required”. This is the most common misjudgement among Chinese exporters.

The real obligation list for Class I:

• Safety and effectiveness: all applicable requirements in sections 10-20 must still be met, with objective evidence retained (section 9(2));
• Labelling: sections 21-23 still apply (including language requirements);
• Incident reporting: sections 59-61.1 still apply;
• Entity qualification: manufacturers, importers and distributors all need an MDEL – but a manufacturer that sells only through MDEL-holding channels may be exempt (section 44(2)(d)).

Basis: Sections 9(2), 10-20, 21-23, 44(2)(d) and 59-61.1 of the Regulations; Health Canada’s Guidance on medical device establishment licensing (GUI-0016).

Will on-site inspections come? Possibly. Health Canada conducts on-site inspections of facilities both inside and outside Canada to verify compliance. Class I’s low barrier means “a low market-entry threshold”, not “low regulatory intensity”.

Q6 What exactly must be submitted for an MDL? (broken down by class)

Bottom line: Five common items plus class-specific material, with depth escalating by class.

Common items (section 32(1), all classes): the device name; the class; the identifier (including identifiers of any system, test kit, device group, device family or other constituent parts); the name and address of the manufacturer shown on the label; and the name and address of the actual place of manufacture (if different from the former).

Class II additions (section 32(2)): a description of the intended use and indications; a list of the standards applied; an executive declaration that objective evidence demonstrates conformity with sections 10-20; draft labels; an investigational testing undertaking for near-patient IVDs; and the quality management system certificate (ISO 13485).

Class III additions (section 32(3)): a description of the device and its materials; an explanation of functional features; a summary of countries of sale, volumes, problems and recalls abroad; the standards applied in design and manufacture; the sterilization method; abstracts and conclusions of all studies; labels; an abstract of investigational testing for near-patient IVDs; a bibliography; and the quality system certificate (design + manufacture).

Class IV additions (section 32(4)): on top of Class III, further requirements including a risk analysis (with risk reduction measures), a quality plan, material specifications, manufacturing processes, detailed information on all studies (pre-clinical, clinical, process validation, software validation, literature studies), and objective evidence of biological safety regarding animal or human tissues.

Basis: Sections 32(1)-(4) of the Regulations.

One frequent misunderstanding: the “summary of foreign sales and recalls” required for Class III/IV is the reviewer’s first entry point into a product’s real-world performance. Missing data is more fatal than unflattering data.

Part 2: Submission and Review: Timelines, Formats and Fees

Q7 Can a product without a licence enter Canada first?

Bottom line: There are three narrow doors, but none of them is a routine commercial pathway.

• Special Access Program (SAP): applied for by medical professionals for specific patients, allowing use of unlicensed devices in emergencies or when conventional therapies have failed, are unavailable, or are unsuitable.
• Investigational Testing Authorization (ITA): for conducting clinical trials in Canada.
• Exceptional importation for shortages (sections 62.27-62.32): for devices in shortage or at risk of shortage in Canada, MDEL holders may import alternative devices authorised by certain foreign regulatory authorities, which are listed publicly by Health Canada. This mechanism became a permanent regime in March 2022.

All three pathways have clear boundaries of applicability and termination conditions, and none can be used as a means of circumventing the MDL.

Basis: Sections 62.27-62.32 of the Regulations; Health Canada’s Guide on the exceptional importation and sale of medical devices in response to shortages (GUI-0147); the official SAP and ITA pages.

Q8 How many models can one licence cover?

Bottom line: Devices may be grouped by family/group/system, but every device’s identifier must be listed individually in the application.

Section 32(1)(c) of the Regulations requires the application to state the device identifier, “including the identifier of any device that belongs to a system, test kit, device group, device family or device group family”. Grouped submissions are therefore permitted, but the basis of grouping (the definition of the same family/group) and the list must be clear, and any subsequent identifier change triggers the amendment obligation (section 34(1)(e)).

Basis: Sections 32(1)(c) and 34(1)(e) of the Regulations.

Q9 How long does review actually take?

Bottom line: What is published is a service standard, not a statutory deadline, and the “clock” can pause for deficiency responses.

Per the performance standards table accompanying the Fees in Respect of Drugs and Medical Devices Order:

Three points must be understood together:

• This is a performance commitment; a fee-refund mechanism applies under the Fees Order when the standard is missed, but it does not change the substance of the review;
• The clock starts on the day an administratively complete application is accepted, not the day of submission;
• After a deficiency notice the clock pauses and resumes once the response is filed – for an MDEL each stoppage may last at most 30 business days, and if the standard is still missed after two deficiency notices, the application is refused.

Basis: Health Canada’s Performance Standards for the Fees in Respect of Drugs and Medical Devices Order; Guidance on medical device establishment licensing (GUI-0016) and the FRM-0292 instructions; Guidance on managing applications for medical device licences (version of November 21, 2025, effective February 2, 2026).

Q10 What new rules in 2026 will affect submissions?

Bottom line: One hard change – from April 1, 2026, Class II-IV applications must be submitted through CESG + REP, with dossiers prepared in the IMDRF ToC format.

Health Canada’s notice is explicit: from April 1, 2026, manufacturers must use the Common Electronic Submission Gateway (CESG) and the Regulatory Enrolment Process (REP). Coverage includes: Class II-IV new applications and amendments, minor changes (faxback), private label applications and amendments, responses to terms and conditions (section 36), responses to requests for supplementary information (section 39), and responses to licence suspension (sections 40 and 41).

At the same time, all regulatory submissions must use the IMDRF Table of Contents format. New applicants submitting a first application must first submit the Company (CO) template XML before applying for a licence.

Not covered: ITA, MDEL, SAP, and devices under Part 1.1 (urgent public health need).

Basis: Health Canada’s notice “Mandatory use of the regulatory enrolment process for medical devices” (April 24, 2026); Guidance on the IMDRF table of contents for medical device applications.

The practical impact on companies: the old approach of “one PDF for everything” is obsolete; dossier structure, file naming, path length and file-system compatibility have all become formal elements on which a submission can be screened out.

Q11 How much does it cost? (rates from April 1, 2026)

Bottom line: Fees fall into three blocks, adjusted annually on April 1 in line with the CPI.

1. Licence application review fees (per application)

2. Establishment licence (MDEL): CAD 5,519 (the same fee schedule applies to the application and the annual licence review).

3. Annual Right to Sell fee: CAD 460 per licence per year, covering the 12 months starting November 1 each year.

Reduction: small businesses may apply for a fee reduction (25% for MDEL-category fees), but small-business status must be obtained from Health Canada before submitting the application; it cannot be granted retroactively.

Basis: Health Canada fee pages (published December 1, 2025, effective April 1, 2026); section 4.1 of the Fees in Respect of Drugs and Medical Devices Order (annual CPI adjustment).

Q12 What are the hard requirements for the quality management system certificate?

Bottom line: It must be a QMS certificate issued by a registrar recognised by Health Canada and audited under MDSAP; valid for no more than 3 years; and any new certificate must be reported to the Ministry within 30 days.

Four key points:

• Standard: CAN/CSA-ISO 13485. Class II covers “manufacture”; Class III/IV covers “design and manufacture” (sections 32(2)(f), 32(3)(j) and 32(4)(p)).
• Issuer: a registrar recognised by the Minister under section 32.1.
• MDSAP is the only route: since January 1, 2019, Health Canada has accepted only certificates issued by MDSAP Auditing Organizations; CMDCAS certificates are no longer accepted. One MDSAP audit simultaneously covers the requirements of Australia, Brazil, Japan, the US and Canada.
• Validity and reporting: the certificate is valid for no more than 3 years (section 32.2); if the registrar is suspended or withdraws, or the certificate expires without renewal, the Minister must be notified within 15 days (sections 32.3 and 32.4); and the manufacturer must submit a copy of any new or amended certificate to the Minister within 30 days (section 43.1).

Basis: Sections 32.1, 32.2, 32.3, 32.4 and 43.1 of the Regulations; Health Canada’s Guidance Document – Requirements in the Recognition Process for MDSAP Auditing Organizations; Notice – Transition Plan for the Medical Device Single Audit Program (MDSAP).

That 30-day obligation under section 43.1 is the most common “technical violation” found in inspections – the certificate changed and the quality system is fine, but without reporting to the Ministry, compliance is still not achieved.

Part 3: System-Level Judgements: Review Depth, Mutual Recognition and Changes

Q13 Is Class II a “filing” system, with only Class III/IV substantively reviewed?

Bottom line: The direction of this statement is right, but the wording is inaccurate.

The accurate statement is:

• Class II: no full technical dossier is submitted; the core is an executive declaration plus retained objective evidence (section 32(2)(c)). Health Canada performs a formal and key-point review, and the company bears the responsibility that “the evidence is in my hands”. This is “declaration-based compliance”, not a “filing” – a false declaration constitutes misrepresentation.
• Class III/IV: study abstracts (III) or study details (IV), risk analysis, quality plan, clinical evidence and so on are submitted, entering substantive technical review. Clinical evidence requirements follow the Guidance on clinical evidence requirements for medical devices, proportionate to the risk class.

Basis: Sections 32(2)(c), 32(3)(f)(i), 32(4)(d)(e)(i)(l) of the Regulations; Health Canada’s Guidance on clinical evidence requirements for medical devices.

Q14 With an FDA 510(k) or a CE certificate, can it be converted directly into a Canadian licence?

Bottom line: No. The Regulations contain no mutual recognition or conversion provision.

The only available “tailwinds” are three, and all of them are at tool level, not access level:

• MDSAP: one system audit satisfies the QMS requirements of five countries – it saves audit cost, not review;
• IMDRF ToC: an internationally uniform dossier structure – it saves filing cost;
• Foreign data can serve as supporting evidence: but sections 32(3)(c) and 32(4)(c) conversely require proactive disclosure of foreign sale countries, volumes, problems and recalls – meaning FDA warning letters and CE NB nonconformities are mandatory disclosures in Canada, not optional ones.

Basis: Sections 32(3)(c) and 32(4)(c) of the Regulations; the relevant MDSAP and IMDRF ToC guidance documents; the Regulations contain no mutual recognition clause.

Q15 Which changes require a licence amendment?

Bottom line: Six situations; check each one rather than judging by feel.

Section 34 of the Regulations lists:

• (a) a significant change to a Class III or IV device;
• (b) a change that would alter the device’s classification;
• (c) a change in the manufacturer’s name;
• (d) a change in the device name;
• (e) a change in the device identifier (including identifiers of any device within a system, test kit, device group or device family);
• (f) a change in the intended use, purpose or indications of a Class II device (other than decorative contact lenses).

“Significant change” is defined in section 1: a change that could reasonably be expected to affect the safety or effectiveness of the device, including changes to manufacturing processes/facilities/equipment, quality control procedures, design (performance, principles, materials, energy, software, accessories) and intended use (new or extended uses, added or removed contraindications, changes to the basis of the shelf life).

Basis: Section 1 (definition of significant change) and section 34 of the Regulations; Health Canada’s guidance interpreting significant changes.

The reverse rule matters just as much: changes not listed in section 34 are handled through the annual renewal declaration (section 43) or the minor change (faxback) channel, without an amendment application. Using the wrong channel wastes review resources and may trigger a request for correction.

Q16 Must labels be bilingual in English and French?

Bottom line: It depends on the scenario – one official language is sufficient in general cases; sale to the general public requires bilingual labelling.

Section 23 of the Regulations has a three-tier structure:

• Section 23(1): the information required by section 21(1) must appear in at least one of English or French;
• Section 23(2): if the instructions for use are provided in only one official language at the time of sale, the manufacturer must provide the other official language version promptly at the purchaser’s request;
• Section 23(3): for devices sold to the general public, the information in paragraphs 21(1)(a) and (e) to (j) must appear in both English and French.

The information required by section 21(1) comprises 10 items, including: the device name, the manufacturer’s name and address, the identifier, the Class III/IV control number, a description of the package contents, the sterilization status symbol, the expiry date, the intended use and performance specifications, directions for use, and special storage conditions (section 21(2) additionally requires the label to be clear, durable, prominent and readily comprehensible to the intended user).

Basis: Sections 21, 22 and 23 of the Regulations.

Practical risk point: once a home-use, OTC or consumer product is deemed “sold to the general public”, bilingual labelling is mandatory; English-only packaging is directly non-compliant, not merely “an area for improvement”.

Part 4: Post-Market: Reporting Clocks and Keeping the Licence

Q17 Once something happens, how fast must it be reported?

Bottom line: Three clocks – 10 days, 30 days and 72 hours – with different triggers.

1. Incident reporting (sections 59-61) – manufacturers and importers each bear their own reporting obligation:

• Death or a serious deterioration in the health of a patient, user or other person: preliminary report within 10 days of becoming aware (section 60(1)(a)(i));
• No death or serious deterioration in health, but it could lead to such if the incident recurs: preliminary report within 30 days of becoming aware (section 60(1)(a)(ii));
• Incidents occurring outside Canada: report as soon as possible after the manufacturer has indicated to a foreign regulatory authority that it will take corrective action, or after that authority has requested it to take corrective action (section 60(1)(b));
• Final reports are submitted according to the timeline set out in the preliminary report (section 61(1));
• With the manufacturer’s written authorisation, an importer may report on its behalf (section 61.1), but the manufacturer must inform Health Canada of this in writing.

2. Serious health hazard information (section 61.2) – applies to MDL holders and to MDEL holders importing Class II-IV devices:

• Triggering content: risks notified by foreign authorities on Health Canada’s list of regulatory authorities, labelling change requests, and foreign recalls/reassessments/licence cancellations or suspensions;
• Deadline: within 72 hours of receipt or awareness (section 61.2(3)).

Basis: Sections 59, 60, 61, 61.1 and 61.2 of the Regulations.

Note that section 61.2 applies to “MDEL holders importing Class II-IV devices” – meaning a Canadian importer is not merely passing goods along; it is an entity that independently bears the 72-hour reporting obligation.

Q18 How is a recall reported?

Bottom line: Notify within 24 hours of the recall decision, submit an initial recall report when the recall begins, and submit a final report within 30 calendar days of completion.

• Reportable scope (section 63.1): when a device may present a health hazard to patients, users or other persons, or may cause serious injury, sections 63.2, 64 and 65 apply to manufacturers and importers;
• 24-hour notice (section 63.2): submit the initial notice within 24 hours of the decision to conduct a recall in Canada;
• Initial recall report (section 64): submitted on or before the day the recall begins; the recall start date is the date on which the recall notices begin to be issued (e.g., the date of the recall notification letters);
• Final recall report (section 65): submitted within 30 calendar days of completing the recall;
• Record retention (section 65.6): manufacturers keep records for the longer of the device’s expected service life plus 2 years, or the period during which the device was sold in Canada; other parties keep records for the expected service life plus 2 years, counted from the completion of the recall.

Basis: Sections 63.1, 63.2, 64, 65, 65.1 and 65.6 of the Regulations; Health Canada’s Guide for recalling medical devices (GUI-0054).

An easily underestimated definitional point: Canada’s definition of “recall” is broader than that of most countries – field corrections, label replacements, and notices telling users to stop using a device can all constitute recalls. A field safety corrective action performed abroad is very likely a reportable recall in Canada.

Q19 Do licences expire? How are they maintained?

Bottom line: The MDL has no fixed validity period, but an annual renewal must be completed before November 1 each year; the MDEL requires an annual licence review before April 1 each year. Missing the deadline is not a fine – it is licence cancellation.

MDL (section 43):

• Before November 1 each year, submit a declaration signed by the manufacturer or its authorised representative in the form required by the Minister, confirming that the information and documents previously submitted remain correct, or explaining the changes (section 43(1));
• If this is not done, the Minister may cancel the licence (section 43(2));
• If sales in Canada cease, the Minister must be informed within 30 days of cessation, and the licence is cancelled upon notification (section 43(3));
• Renewal rhythm: Health Canada sends out the renewal package in early August each year -> the company returns it before November 1 -> invoices are issued in December and payable within 30 days -> unpaid fees can be pursued through the government receivables process.

MDEL (GUI-0016):

• Submit the Annual Licence Review (ALR) application before April 1 each year;
• Changes to the information under paragraphs 45(a) and (b) (establishment names and addresses, contact information) must be notified within 15 calendar days.

Basis: Sections 43 and 45 of the Regulations; Health Canada’s Guidance Document – Medical Device Licence Renewal and Fees for the Right to Sell Licensed Medical Devices; Guidance on medical device establishment licensing (GUI-0016).

There is no “reinstatement” channel after cancellation – a new application with new fees is required. This is the costliest single lapse in annual compliance.

Q20 Is a “summary report” also required post-market?

Bottom line: Yes. Class II every two years and Class III/IV annually, with written notice within 72 hours if the conclusions change.

• Cycle (section 61.4(1)): Class II once every two years, covering the preceding 24 months; Class III and IV once a year, covering the preceding 12 months;
• Content (section 61.4(2)): adverse effects, problems within the meaning of section 57(1)(a), incidents within the meaning of section 59(1), and serious health hazard risks within the meaning of section 61.2(2);
• Analysis requirement (section 61.4(3)): the report must include a concise critical analysis;
• Change determination (section 61.4(4)): the report must assess whether known benefits and risks have undergone one of three types of change – benefits may decrease, the probability or severity of risks has increased, or a new risk has been identified;
• 72-hour notice (section 61.4(6)): if the conclusion is that a change has occurred, the Minister must be notified in writing within 72 hours of reaching that conclusion;
• Records and requests: records are kept for 7 years from the date of creation (section 61.6(2)); the Minister may request the summary report or the information on which it is based at any time (section 61.5).

Basis: Sections 61.4, 61.5 and 61.6 of the Regulations; Health Canada’s Guidance on summary reports and issue-related analyses for medical devices.

Appendix: seven high-frequency pitfalls (practical observations, not regulatory provisions)

• Treating “Class I needs no registration” as “no compliance” – labelling, incident reporting and MDEL entity qualification are all still required.
• Failing to report a new certificate to the Ministry within 30 days (section 43.1) – the quality system is fine, but the procedure is already violated.
• Significant changes without an amendment application – especially manufacturing processes, sites, software and intended use; these four are the easiest to miss.
• Late annual renewal – the result is licence cancellation; only a new application and new fees can restore it.
• Submitting CE/FDA documents with just a new cover page – missing IMDRF ToC structure and foreign sales/recall disclosure; screened out in the first round.
• Handling label language by “export habit” – for products sold to the general public, English-only packaging is non-compliant.
• Overlooking the importer’s independent reporting duty – MDEL holders importing Class II-IV devices bear the 72-hour reporting responsibility themselves; it is not waived because the manufacturer has already reported.

Closing thought: Canada is not “one more market” – it is “one more foundational capability”.

After these 20 questions, you will find that the real character of Canadian regulation lies not in severity but in closure:

Classification rules determine evidence depth -> evidence depth determines the review pathway -> MDSAP determines system credibility -> the annual renewal and the 72-hour clocks determine whether the licence can be kept.

In none of these four links can gaps be papered over with last-minute material. It requires companies to build a mechanism that can run over the long term across three lines – quality system, change control and post-market surveillance – before submission.

Canada’s threshold was never only inside the dossier. It lives in your change-control records, in your annual renewal calendar, and in the first 72 hours after you learn of a foreign recall.

Sources

• Medical Devices Regulations, SOR/98-282 (consolidated version current as of 2026-09-30) – Department of Justice Canada regulations database, laws-lois.justice.gc.ca/eng/regulations/SOR-98-282/
• Food and Drugs Act – laws-lois.justice.gc.ca
• Fees in Respect of Drugs and Medical Devices Order, SOR/2019-124
• Health Canada: Fees for examining a licence application… for medical devices (rates from 2026-04-01)
• Health Canada: Fees for the examination of an application for an establishment licence: medical devices
• Health Canada: Fees for the right to sell licensed or authorized Class II, III or IV medical devices
• Health Canada: Guidance on medical device establishment licensing (GUI-0016)
• Health Canada: Medical Device Establishment Licence (MDEL) application: instructions (FRM-0292)
• Health Canada: Guidance on managing applications for medical device licences (version of 2025-11-21, effective 2026-02-02)
• Health Canada: Guidance Document – Medical Device Licence Renewal and Fees for the Right to Sell Licensed Medical Devices
• Health Canada: Guide for recalling medical devices (GUI-0054)
• Health Canada: Guidance on summary reports and issue-related analyses for medical devices
• Health Canada: Guidance Document – Requirements in the Recognition Process for MDSAP Auditing Organizations
• Health Canada: Notice – Transition Plan for the Medical Device Single Audit Program (MDSAP)
• Health Canada: Mandatory use of the regulatory enrolment process for medical devices (2026-04-24)
• Health Canada: Guidance on the IMDRF table of contents for medical device applications
• Health Canada: Guidance on terms and conditions for Class II to IV medical devices
• Health Canada: Guide on the exceptional importation and sale of medical devices in response to shortages (GUI-0147)
• Health Canada: Performance Standards for the Fees in Respect of Drugs and Medical Devices Order

Disclaimer: All regulatory statements in this article were verified against the official texts listed above. Section numbers and figures are governed by the current consolidated version on the Department of Justice Canada website and by Health Canada’s official publications. The regulations are subject to continuous amendment (e.g., SOR/2024-238, SOR/2026-96); verify against the latest version when applying them to specific projects. This article does not constitute legal advice; professional conclusions on classification and change determinations should be made in light of the technical documentation of the specific product.